Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 229 of the 234 references it cites were found in a registry or an index; 29 of the 182 sources its claims cite were checked for support.

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Open access

Abstract

Cancer of the colon and rectum (CRC) has been identified among the three most prevalent types of cancer and cancer-related deaths for both sexes. Even though significant progress in surgical and chemotherapeutic techniques has markedly improved disease-free and overall survival rates in contrast to those three decades ago, recent years have seen a stagnation in these improvements. This underscores the need for new therapies aiming to augment patient outcomes. A number of emerging strategies, such as immune checkpoint inhibitors (ICIs) and adoptive cell therapy (ACT), have exhibited promising outcomes not only in preclinical but also in clinical settings. Additionally, a thorough appreciation of the underlying biology has expanded the scope of research into potential therapeutic interventions. For instance, the pivotal role of altered telomere length in early CRC carcinogenesis, leading to chromosomal instability and telomere dysfunction, presents a promising avenue for future treatments. Thus, this review explores the advancements in CRC immunotherapy and telomere-targeted therapies, examining potential synergies and how these novel treatment modalities intersect to potentially enhance each other’s efficacy, paving the way for promising future therapeutic advancements.

Overview

CoChat Summary

TL;DR

This narrative review summarizes current and emerging immunotherapy for colorectal cancer (CRC), including immune checkpoint inhibitors (ICIs), adoptive cell therapy (ACT), vaccines, and telomere/telomerase-targeted strategies. It highlights dMMR/MSI-H as the main immunotherapy-responsive subset and proposes telomere length and telomerase activity as potential prognostic/predictive biomarkers and adjunct targets.

Key findings

  • dMMR/MSI-H is identified in roughly 15% of all CRC patients and 5% of metastatic CRC (mCRC) patients; by stage, it accounts for about 15–18% of stage II, ~10% of stage III, and ~5% of stage IV cases. ICIs benefit this subset, but approximately 15–29% develop immune resistance.
  • FDA-approved ICIs for CRC include nivolumab (since 1 August 2017 for MSI-H/dMMR mCRC, based on CheckMate 142), pembrolizumab (since 29 June 2020 as first-line for unresectable or metastatic MSI-H/dMMR CRC, based on KEYNOTE-177), and nivolumab plus ipilimumab for previously treated MSI-H/dMMR mCRC. Atezolizumab did not achieve its primary endpoint of improved overall survival in previously treated mCRC.
  • As of January 2024, 14 clinical trials were underway assessing TIL cells for CRC; TIL therapy produced objective regression of multiple lung metastatic lesions in mCRC after infusion of HLA-C*08:02-restricted TILs targeting KRAS G12D.
  • Telomere/telomerase findings: annual telomere shortening is approximately 20–40 base pairs; telomerase activity is detected in 80–100% of CRC tumor samples versus 9–53% of normal mucosa samples; high TERT and/or telomerase activity is typically associated with poorer prognosis. Longer telomere length was associated with better overall survival regardless of cancer type in one cited study, but had no effect on response to ICI therapy.

Methods

  • Design: narrative review of immunotherapy and telomere-targeted therapies in CRC.
  • Data: published preclinical and clinical literature, including cited phase II/III trials, meta-analyses, and ClinicalTrials.gov registrations.
  • Analysis: qualitative synthesis of immune checkpoint biology, ACT, vaccine platforms, biomarkers, and telomere/telomerase dynamics; no systematic search strategy, meta-analysis, or primary patient data are described.

Limitations

  • Stated limitations: Not stated in the paper.
  • Evident from the text: as a narrative review, it does not report a systematic search strategy, inclusion criteria, or risk-of-bias assessment, so selection and publication biases cannot be excluded.
  • Evident from the text: many cited findings come from heterogeneous settings (preclinical models, phase I/II trials, retrospective studies, and ongoing trials), and proposed synergies between telomere status and ICIs/ACT are largely presented as hypotheses rather than tested in the reviewed clinical trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cancers16111995

Cites

229 of 230 references verified1 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 A graphical presentation of T cells infiltrating a tumor site in MSI-H CRC as a result of the increased mutational burden induced by the deficient mismatch repair system.
Figure 1 A graphical presentation of T cells infiltrating a tumor site in MSI-H CRC as a result of the increased mutational burden induced by the deficient mismatch repair system.CC BY · PubMed Central
Figure 2 Graphical presentation of T-cell activation through the PD1/CTLA-4 pathway. Dendritic cells are able to activate T cells through the cross talk of the transmembrane proteins MHC II and TCR/CD4. However, this activating interaction can be canceled downstream if PD-L1/2 and CD80/86 expressed on the surface of dendritic cells connect with PD-1 and CTLA-4, respectively. This deactivating action can be counteracted through the inhibition of anti-PD-1/antiCTLA-4 antibodies. This allows activated T cells to enter the tumor microenvironment and eliminate cancer cells.
Figure 2 Graphical presentation of T-cell activation through the PD1/CTLA-4 pathway. Dendritic cells are able to activate T cells through the cross talk of the transmembrane proteins MHC II and TCR/CD4. However, this activating interaction can be canceled downstream if PD-L1/2 and CD80/86 expressed on the surface of dendritic cells connect with PD-1 and CTLA-4, respectively. This deactivating action can be counteracted through the inhibition of anti-PD-1/antiCTLA-4 antibodies. This allows activated T cells to enter the tumor microenvironment and eliminate cancer cells.CC BY · PubMed Central

Verification

Claims the paper makes

23 Valid · 4 Not valid · 117 Not checked · 15 Own results and interpretations

78 more claims · 12 with their cited sources checked

Create a free account to see all 159 claims and to verify the 153 references still open.

See all claims — free account
  • It may state two separate claims as one. 50
  • Probably not a substantial claim. 37
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 234 references

Cited by

See all 40

Metadata

Authors
Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A.
Affiliations
  • Department of General Surgery, University General Hospital of Heraklion, 71110 Heraklion, Greece
  • University Hospital of Heraklion (GR)
  • University of Medicine and Pharmacy of Craiova (RO)
  • University of Crete (GR)
Corresponding author
Docea, Anca Oana
Venue
Cancers
Publisher
MDPI AG
Published
2024-05-24
Volume
16
Issue
11
Pages
1995
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4398784015
Cited by
37
References
234
Citations by year
2026: 15 · 2025: 18 · 2024: 4
FWCI
1.98
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
colorectal cancer, immunotherapy, immune checkpoint inhibitors, adoptive immunotherapy, telomere length, telomere dysfunction, chromosomal instability, carcinogenesis, cancer treatment trends

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy. https://app.cochat.ai/papers/10.3390/cancers16111995
The paper
Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024). Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy. Cancers. https://doi.org/10.3390/cancers16111995

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.